INCY240920C65000
- 2.98
- +0.83+38.60%
Incyte Newsroom
Incyte's Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics
Incyte Closes 5% Higher Bolstered by Zynyz Data, Guggenheim Note
Incyte Insider Sold Shares Worth $526,948, According to a Recent SEC Filing
Incyte Announces Promising New Data on Oncology Candidate at ESMO
Incyte Shares Are Trading Higher After B of A Securities and Guggenheim Raised Their Respective Price Targets on the Stock.
Incyte Is Maintained at Buy by Guggenheim
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $64 to $92
On Sep 16, major Wall Street analysts update their ratings for $Incyte(INCY.US)$, with price targets ranging from $64 to $92.Morgan Stanley analyst Vikram Purohit maintains with a hold rating, and
B of A Securities Maintains Neutral on Incyte, Raises Price Target to $68
TD Cowen Sticks to Its Buy Rating for Incyte (INCY)
Express News | Incyte : Guggenheim Raises Target Price to $92 From $86
Incyte's Promising Clinical Data Balanced With Regulatory Uncertainty: A 'Hold' Recommendation
Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal...
Reported Saturday, Incyte Unveils Results For CDK2 Inhibitor INCB123667 In Advanced Solid Tumors, Ovarian Cancer Among Highlighted
Incyte Zynyz Improves Progression-free Survival in Anal Cancer
Unusual Options Activity: F, INCY and Others Attract Market Bets, F V/OI Ratio Reaches 416.7
EST Sep 12th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
BofA Securities analyst Tazeen Ahmad maintains $Incyte(INCY.US)$ with a hold rating, and adjusts the target price from $62 to $66.According to TipRanks data, the analyst has a success rate of 50.7%
Incyte's CDK2i: A Cautiously Optimistic Neutral Rating Amidst Early Clinical Data and Safety Concerns
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings